

# **LiteHaus360 MarketPlaces**

**Life Sciences**

**&**

**Technology Incubator**

**//**

**Company Falcon - Business Summary**

30<sup>th</sup> June 2022

## **Company Falcon:: Organoid technology to develop new class of drugs for treatment of cancer and metastatic disease**

### **About Falcon**

Company Falcon was founded with the aim to develop immortalized cell lines from different tissues for research purposes. From there the company advanced its portfolio into the development of organoids as models for disease modeling and drug R&D. The Company's Founder obtained his PhD from the Tata Institute of Fundamental Research, Mumbai, and brings extensive research experience of 45+ years in cell and molecular biology from organizations such as the US NCI, NIH and NHLBI. He conducted research at a major global Japanese pharmaceutical company and served as faculty at The Johns Hopkins University School of Medicine. He has published several research papers in peer reviewed popular scientific journals and owns three US patents on the development of novel scientific methods for basic and applied research.

### **Description**

1. Falcon has developed an entirely new paradigm confirmed by unequivocal experimental evidence to develop a new class of drugs to treat cancers and metastatic disease. The presence of a common epigenetic growth regulator (EGR) responsible for unregulated growth of a range of cancers has been conclusively established by a novel cell growth activation assay. Such EGR is not present in normal and non-malignant cells. In addition, cell biology tools necessary to identify the chemical nature of EGR have been developed. An entirely new class of drugs can be developed targeted to the EGR present only in malignant cells.
2. Falcon has developed an efficient method to prepare organoid cultures from fresh solid tumor specimens. This method involves a proprietary medium and specific growth surface to enrich for tumor cells in the organoids. The method does not involve transfer of exogeneous genes or other cellular components from other cell types for development of organoids. The Company can rapidly establish organoids - several thousand depending upon the quality and size of tumor sample - from 300 - 400 mg of tumor tissue. These organoids can be cryopreserved and thawed with >80% functional recovery. Once developed, they can be maintained for several weeks in

culture facilitating their application for drug development and testing. Falcon organoids can be fully sequenced to reveal the genetic makeup of the specific donor and therefore have an immense predictive, precision and prognostic value in cancer therapeutics.

Strategies to screen antagonists (small molecule inhibitors) to the validated lncRNA/micro-RNA/Protein targets will form the basis to develop drugs to treat different types of cancer and metastasis. Such drugs are expected to have no or minimal side effects since these targets are not present in normal non-cancerous cells. It may also be possible to give such drugs targeted to EGR prophylactically to individuals with a predisposition to cancer. The technology has a high probability of success owing to its unique construction and pathophysiological features.

### **About LiteHaus360**

Falcon is housed within the LiteHaus360 incubator – a virtual ecosystem that offers entrepreneurs, start-ups as well as growth phase companies with key strategic, operational and financial advisory to advance on their objectives to bring novel technologies into the healthcare system ultimately to bring life-saving medicines to patients.

LiteHaus360 offers a unique platform to founders by enabling them to showcase their businesses on the LiteHaus MarketPlace thereby reaching a global audience in their specific industry. Once listed on the StoreFront, LiteHaus assists incubatee companies network with the user community to spur adoption as well as raise capital by reaching an extensive network of biopharma companies, academic institutions and VC/PE funds.

--

### **For more information:**

Harsh Bal, PhD

CEO, LiteHaus360

t: 302 476 0518

e: [harsh@litehaus360.com](mailto:harsh@litehaus360.com)

e: [harshawardhan.bal.wm17@wharton.upenn.edu](mailto:harshawardhan.bal.wm17@wharton.upenn.edu)

w: [www.litehaus360.com](http://www.litehaus360.com)